Bone Fracture – VJRegenMed

Healing diabetic ulcers with nanoclays

Simon Ng — Mon, 17 Jan 2022 18:10:25 +0000

Jonathan Dawson, PhD, University of Southampton, Southampton, UK, gives an overview of utilizing nanoclays in treating diabetic foot ulcers. Nanoclays can concentrate proteins from the surrounding area, and administration of vascular endothelial growth factor (VEGF) in the wound area has shown to stimulate angiogenesis and thus enhance wound repair in patients with diabetes. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Future applications of BMP-2

Simon Ng — Thu, 13 Jan 2022 16:36:08 +0000

Bone morphogenetic protein 2 (BMP-2) is a growth factor currently used for spinal fusion in patients. Jonathan Dawson, PhD, University of Southampton, Southampton, UK, comments on potential applications of BMP-2 beyond fusing spinal discs in the lower spine. Due to high concentrations of BMP-2 required, it is only administered in the lower spine. Dr Dawson discusses research being carried out to safely use BMP-2 in other areas of the spine and in an outpatient setting. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Clinical translation of regenerative nanoclays

Simon Ng — Mon, 10 Jan 2022 15:38:50 +0000

Jonathan Dawson, PhD, University of Southampton, Southampton, UK, provides an overview of barriers to developing regenerative nanoclays for the clinic. Refining the manufacturing process so that the final product adheres to good manufacturing process (GMP) standards and is clinical-grade is important. As the nanoclay additionally contains bone morphogenetic protein 2 (BMP-2), classification of the product may present challenges to regulatory authorities, and varying regulatory requirements across different countries will also present potential barriers. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Regenerative nanoclays in bone regeneration

Simon Ng — Mon, 10 Jan 2022 15:38:48 +0000

Jonathan Dawson, PhD, University of Southampton, Southampton, UK, describes the mechanism of action of regenerative nanoclays. Nanoclays have reversible gel-like properties when in water and can attract proteins with their charge. These properties enable nanoclays to be used in bone growth, as growth factors including bone morphogenetic protein 2 (BMP-2) can aggregate within the nanoclay and be delivered to a localized area, reducing the dosage needed. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Healing bone defects with 3D scaffolds and biomimetic film

Simon Ng — Wed, 05 Jan 2022 17:32:19 +0000

Charlotte Garot, CEA Grenoble, Grenoble, France, describes research on 3D printed scaffolds combined with 2D osteoinductive coatings to repair bone defects that cannot heal by themselves. Bone autografts require several surgeries and patients may have a limited selection of bone suitable for grafting. A personalized, 3D printed scaffold with a 2D film that mimics the extracellular matrix can stimulate bone growth by releasing bone morphogenetic protein 2 (BMP-2). Initial studies in sheep models have demonstrated promising efficacy, with a lower dose of BMP-2 needed than in current clinical settings. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Future strategies in bone regeneration

Simon Ng — Wed, 05 Jan 2022 17:32:17 +0000

Charlotte Garot, CEA Grenoble, Grenoble, France, discusses the role of regenerative medicine in advancing bone regeneration. An increased focus on using regenerative therapies will result in more personalized treatments for patients, and further research on bone geometry and optimizing bone morphogenetic protein 2 (BMP-2) will be critical to developing effective therapies. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Co-culture systems in bone research

Simon Ng — Tue, 04 Jan 2022 13:03:18 +0000

Sandra Hofmann, PhD, Eindhoven University of Technology, Eindhoven, The Netherlands, describes the role of bone co-cultures in understanding the pathophysiology of bone diseases. Recreating the cellular conditions in a healthy and diseased state can improve our understanding of how drugs interact in various environments as well as their mechanism of action. Whilst bones have regenerative potential without the need for external stimuli, further research is additionally required for the development of scaffolds in patients with larger bone fractures. This interview took place at 6th world congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).

Developing iPSC-derived MSCs for therapeutic purposes

Simon Ng — Wed, 20 Oct 2021 17:41:42 +0000

Miguel Forte, MD, PhD, Bone Therapeutics SA, Gosselies, Belgium, discusses the recently announced research partnership between Bone Therapeutics and Implant Therapeutics, which aims to drive the development of hypoimmunogenic induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cell (MSC)-based therapies for various indications. Dr Forte explains that the implementation of iPSC technology offers the potential to optimize the effects of current MSC-based therapies such as ALLOB, an allogeneic MSC-based cell therapy platform being investigated for bone regeneration in orthopedic indications. This interview took place at the Advanced Therapies Congress & Expo 2021.

Off-the-shelf cell therapy for bone indications: ALLOB & JTA-004

admin_vjr_user — Thu, 24 Jun 2021 17:15:41 +0000

Miguel Forte, MD, PhD, Bone Therapeutics SA, Gosselies, Belgium describes ongoing research investigating allogeneic mesenchymal stromal cell (MSC)-derived osteoblastic cells (ALLOB) for the formation of bone in orthopedic conditions. The safety and efficacy of ALLOB has been tested in patients with degenerative disc disease (NCT02205138) and long bone fractures (NCT02020590), and its impact in tibial fractures is being evaluated in the ongoing Phase IIb ALLOB-TF2 trial (NCT04432389). Dr Forte also describes JTA-004, an intra-articular injectable currently being investigated in patients with knee osteoarthritis (NCT04333160), as well as plans to expand their MSC platform into immunomodulatory conditions. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.